BioSante inks $39M pact on melanoma vax

BioSante Pharmaceuticals is picking up a nominal $100,000 upfront fee from the John P. Hussman Foundation in exchange for an exclusive worldwide license on a preclinical melanoma vaccine. The foundation plans to quickly move the vaccine into clinical trials and is on the hook for up to $39 million in milestones. BioSante also stands to gain up to 33% of any sublicensing revenue. "Assuming a successful outcome of the first Phase I clinical trial, the foundation will fund a Phase II clinical trial with the objective of obtaining further clinical evidence and engaging a corporate sponsor for Phase III clinical trials," says BioSante CEO Stephen Simes. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.